Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESIDE trial in recent-onset primary diplopia due to thyroid eye disease
ChiCTR2500103479Phase 3Not yet recruiting
- Sponsor
- Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital
- Start
- May 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone, sirolimus and mycophenolate sodium in Graves Orbitopathy (GO) (3 arms), sponsored by Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital. Primary endpoint: Primary response rate at week 48. Planned start May 2025; status: not yet recruiting.
02
Drugs
methylprednisolonesirolimusmycophenolate sodium
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2500103479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103479.